Plain-English translation of NCT05979363 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a combination approach—starting with three rounds of chemotherapy drugs (bortezomib, lenalidomide, and dexamethasone), followed by an infusion of specially engineered immune cells called BCMA CAR-T cells—can help patients with primary plasma cell leukemia who are not candidates for stem cell transplant. The study will also include additional rounds of chemotherapy after the cell infusion. Researchers want to see if this combination is both safe and effective for this serious blood cancer.
Primary plasma cell leukemia is an aggressive blood cancer with few treatment options for patients who cannot tolerate or are ineligible for stem cell transplant due to age, overall health, or other medical reasons. This trial explores whether adding this newer immunotherapy approach to standard chemotherapy might improve outcomes for these patients.
You likely qualify if…
You likely don't qualify if…
You would receive three 28-day cycles of combination chemotherapy as an outpatient, with injections and oral medications on specific days each cycle. After that, you would receive a one-time infusion of the engineered immune cells. Following the cell infusion, you would then receive three more cycles of a two-drug chemotherapy combination, followed by ongoing maintenance treatment with the same two drugs. Throughout the study, you would have regular blood tests and clinic visits to monitor how your body is responding and managing any side effects.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China